On this page
Overview
Product & regulatory status
FDA-approved prescription products include Aveed injection and oral Jatenzo; their labels are not interchangeable.
Conversion after absorption
Undecanoate supplies testosterone after ester cleavage. The oral product’s absorption depends on its formulation and food conditions. [1]
What the evidence shows
Oral replacement trial
In the Jatenzo product study, 87% of 166 treated hypogonadal men achieved average testosterone in the reference range at the end of treatment. A hormone-range endpoint does not guarantee relief of every symptom. [1]
A specific symptom population
A 30-week placebo-controlled trial studied long-acting undecanoate in 199 men with type 2 diabetes and low testosterone. Sexual-function benefit depended on deficiency severity; this is not proof of a general libido benefit in men with normal testosterone. [2]
What remains unknown
The shared ester name does not support transferring an oral result to an injectable product or vice versa. Long-term outcomes outside the studied populations remain uncertain.
Safety
Injection-specific serious reactions
Aveed carries warnings for pulmonary oil microembolism and anaphylaxis and requires monitored healthcare administration. These are formulation-specific issues. [3]
Oral-product risks
Jatenzo can increase blood pressure and hematocrit and can suppress sperm production. Avoid equating an oral formulation with absence of systemic risk. [1]
Separate product evidence
Aveed is an oil-based long-acting injectable preparation; its exposure and safety program cannot be applied to capsules. [3]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [4]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [5]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Is oral undecanoate the same as the long-acting injection?
No. They share an ester but have different absorption and product-specific instructions.
What information should I keep with my records?
The brand, formulation and route so that laboratory results and adverse effects are interpreted against the right product.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Jatenzo prescribing informationUS oral testosterone undecanoate label, revised September 2025; product efficacy and blood-pressure risks.
- Hackett et al.: testosterone undecanoate and sexual functionBJU International, 2016; 30-week placebo-controlled trial in 199 men with type 2 diabetes and low testosterone.
- Aveed prescribing informationFDA 2025 label for long-acting testosterone undecanoate injection; formulation-specific pulmonary oil microembolism and anaphylaxis warnings.
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.